INDIANAPOLIS–(BUSINESS WIRE)–Modular Devices Acquisition, LLC (Modular Devices), a leading provider of mobile cath labs and mobile cleanrooms, today announced the acquisition of Cardiac Services Mobile, Inc. (Cardiac Services Mobile), a mobile cath lab company out of Nashville, TN that serves the US markets. The acquisition builds on Modular Devices’ position […]
Other News
Athersys Reports First Quarter 2022 Results
Management to host conference call following announcement of Phase 2/3 TREASURE data in May CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2022. In anticipation of the announcement in May of topline data from Athersys’ partner, HEALIOS K.K. (Healios), for its […]
BD REPORTS SECOND QUARTER FISCAL 2022 FINANCIAL RESULTS
Revenue of $5.0 billion increased 2.1% as reported and 3.9% on currency-neutral basis Revenue driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by decline in worldwide COVID-only testing revenues to $214 million from $474 million in the prior year GAAP diluted EPS of $1.50; adjusted diluted EPS of $3.18 Company raises mid-point of […]
OMRON Healthcare Issues National Health Alert: Pandemic-Driven Trends Are Raising Heart Health Risks
Global heart health leader urges Americans to monitor blood pressure regularly and take action to manage hypertension among increased health risks associated with COVID-19 pandemic HOFFMAN ESTATES, Ill., May 5, 2022 /PRNewswire/ — Global heart health leader,, today issued a national health alert warning of increased heart health risks emerging from the […]
Access Vascular Receives FDA Clearance for HydroPICC® Biomaterial-Based Dual-Lumen Catheter
Single- and dual-lumen biomaterial catheters allow hospitals to reduce thrombosis and vascular access complications for majority of PICC applications BILLERICA, Mass., May 05, 2022 (GLOBE NEWSWIRE) — Access Vascular, Inc. (AVI) today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its HydroPICC® Dual-Lumen catheter. Designed […]
Inari Medical Reports First Quarter 2022 Financial Results
IRVINE, Calif., May 04, 2022 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2022. First Quarter Revenue […]
Eko Recognized with Second Consecutive MedTech Breakthrough Award for AI Innovation in Healthcare
Point-of-care cardiac screening solution honored at sixth annual awards program for improving detection of heart disease OAKLAND, Calif., May 05, 2022 (GLOBE NEWSWIRE) — Eko, a digital health company advancing heart and lung disease detection, today announced that, for the second consecutive year, it has won the “Best Use of Artificial […]
Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update
Conference Call and Webcast at 8:00 am Eastern Time THE WOODLANDS, Texas, May 05, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2022 and provided an update on key milestones. “We plan to resubmit our New Drug Application (NDA) for […]
BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update
–Completed sale to Sentynl Therapeutics of BridgeBio’s NULIBRY™ (Fosdenopterin) for Injection –Updated strategic collaboration with Helsinn Group to develop, manufacture and commercialize infigratinib in oncology indications in the U.S.; BridgeBio is eligible to receive regulatory and commercial milestone payments as well as tiered royalties on adjusted net sales from Helsinn –Released […]
FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
Results from the DELIVER and DAPA-HF Phase III trials demonstrate FARXIGA’s efficacy in heart failure regardless of ejection fraction WILMINGTON, Del.–(BUSINESS WIRE)–High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or […]



